|
SIGA Technologies, Inc. (SIGA): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
SIGA Technologies, Inc. (SIGA) Bundle
In the high-stakes world of biodefense pharmaceuticals, SIGA Technologies stands as a critical guardian against potential viral threats, offering cutting-edge medical countermeasures that could mean the difference between containment and catastrophe. With its flagship product TPOXX and strategic government partnerships, SIGA has positioned itself as a key player in national security preparedness, developing innovative antiviral treatments designed to protect populations from emerging biological risks. Dive into the intricate marketing mix that drives this unique company's mission to safeguard public health at the intersection of science, strategy, and national defense.
SIGA Technologies, Inc. (SIGA) - Marketing Mix: Product
Biodefense Pharmaceutical Focus
SIGA Technologies is a biodefense pharmaceutical company specializing in antiviral treatments with a core focus on developing medical countermeasures for potential biological threats.
Primary Product: TPOXX (Tecovirimat)
TPOXX is the company's flagship pharmaceutical product, approved by the FDA in 2018 for treating smallpox. The drug has the following key characteristics:
| Product Attribute | Specification |
|---|---|
| Generic Name | Tecovirimat |
| FDA Approval Year | 2018 |
| Primary Indication | Smallpox Treatment |
| Dosage Form | Oral Capsules |
Strategic Product Development
SIGA Technologies develops pharmaceutical interventions specifically designed for government and military preparedness against biological threats.
- Develops antiviral treatments for potential biological threats
- Focuses on emerging viral disease interventions
- Provides medical countermeasures for national security preparedness
Government Contracts
The company has secured significant contracts with the U.S. government for medical countermeasure procurement:
| Contract Type | Value | Year |
|---|---|---|
| BARDA Contract | $335 million | 2011 |
| Follow-on Procurement Contract | $198.6 million | 2018 |
Product Portfolio
SIGA's product portfolio is primarily centered on TPOXX, with ongoing research and development in antiviral therapeutic solutions.
- TPOXX: Primary smallpox treatment
- Potential applications for orthopox virus infections
- Ongoing research in antiviral drug development
SIGA Technologies, Inc. (SIGA) - Marketing Mix: Place
Headquarters Location
Located at 530 5th Avenue, 9th Floor, New York City, New York 10036, United States.
Distribution Channels
| Distribution Channel | Primary Target | Procurement Method |
|---|---|---|
| U.S. Strategic National Stockpile | Federal Biodefense Programs | Direct Government Procurement |
| Military Medical Supply Chains | Department of Defense | Contracted Sales |
| Federal Health Organizations | Public Health Emergency Preparedness | Strategic Partnership Agreements |
Key Distribution Strategies
- Direct sales to government agencies
- Specialized procurement through federal biodefense programs
- Targeted distribution to national emergency preparedness networks
Strategic Partnerships
Primary Government Partners Include:
- Biomedical Advanced Research and Development Authority (BARDA)
- Department of Health and Human Services (HHS)
- U.S. Department of Defense
Geographic Market Coverage
Exclusively focused on United States federal and state government markets.
Distribution Infrastructure
| Infrastructure Component | Operational Details |
|---|---|
| Primary Product Distribution | TPOXX (Tecovirimat) for smallpox treatment |
| Inventory Management | Centralized government stockpile allocation |
| Delivery Mechanism | Secure, controlled pharmaceutical supply chain |
SIGA Technologies, Inc. (SIGA) - Marketing Mix: Promotion
Government and Institutional Marketing Strategies
SIGA Technologies focuses exclusively on government and institutional markets for its biodefense products, particularly TPOXX (tecovirimat), used for treating smallpox.
| Marketing Channel | Target Audience | Focus Area |
|---|---|---|
| Federal Procurement | US Strategic National Stockpile | Biodefense Medical Countermeasures |
| Defense Department Contracts | Military Medical Services | Emergency Preparedness |
Conference and Industry Engagement
SIGA actively participates in key biodefense and pharmaceutical conferences to showcase its products.
- World Health Organization (WHO) Biodefense Symposiums
- Centers for Disease Control (CDC) Emergency Preparedness Conferences
- Department of Health and Human Services (HHS) Pharmaceutical Forums
Strategic Communication Channels
SIGA leverages multiple communication strategies to engage with federal health agencies.
| Communication Method | Primary Purpose | Frequency |
|---|---|---|
| Regulatory Submissions | FDA Approvals | Quarterly |
| Scientific Publications | Clinical Research Credibility | Bi-Annually |
Public Health Relationships
SIGA maintains strategic partnerships with key public health organizations.
- National Institutes of Health (NIH) Collaboration
- BARDA (Biomedical Advanced Research and Development Authority) Contracts
- Emergency Management Agencies Partnerships
Promotional Investment
SIGA's promotional expenditures are primarily directed towards government and institutional marketing efforts.
| Fiscal Year | Marketing Expenses | Percentage of Revenue |
|---|---|---|
| 2022 | $3.2 Million | 8.5% |
| 2023 | $4.1 Million | 9.2% |
SIGA Technologies, Inc. (SIGA) - Marketing Mix: Price
Government Contract Pricing Mechanism
SIGA Technologies' pricing strategy is fundamentally determined through complex government contract negotiations, specifically for TPOXX (tecovirimat), their antiviral drug for smallpox treatment.
| Contract Type | Pricing Structure | Total Contract Value |
|---|---|---|
| Biodefense Procurement | Per Treatment Pricing | $479.4 million (2018 HHS Contract) |
| Strategic National Stockpile | Bulk Purchase Agreement | $225.5 million (2021 Renewal) |
Pricing Determinants
Pricing for SIGA's pharmaceutical products is influenced by several critical factors:
- National security requirements
- Emergency preparedness protocols
- Specialized biodefense product capabilities
- Limited competitive landscape
Treatment Cost Breakdown
| Product | Per Treatment Cost | Annual Potential Revenue |
|---|---|---|
| TPOXX | $5,750 per treatment course | Estimated $87.3 million (2023) |
Pricing Strategy Considerations
SIGA's pricing approach emphasizes strategic value over traditional market pricing, focusing on national security implications and unique product positioning.
- Negotiates pricing based on product's critical medical countermeasure status
- Aligns pricing with government procurement guidelines
- Reflects extensive research and development investments
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.